Ticho Barry 4

What Happened Ticho Barry, Chief Medical Officer of Stoke Therapeutics, sold 1,838 shares on April 1, 2026 at $32.66 per share, generating gross proceeds of approximately $60,029. The transaction is reported as a sale (code S).

Key Details

• Transaction date and price: 2026-04-01 — 1,838 shares @ $32.66 each.
• Total proceeds: ~$60,029 (gross).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Footnote: Transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
• Filing timeliness: Report filed April 3, 2026 for an April 1, 2026 trade — appears timely (no late-filing indication).

Context This sale was executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and limits what the trade can indicate about the insider’s current view of the company. Sales by executives can be routine (diversification, tax planning, etc.) and do not necessarily signal negative company prospects; purchases are generally more informative about insider confidence.